Vascular Endothelial Growth Factor A
"Vascular Endothelial Growth Factor A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.
| Descriptor ID |
D042461
|
| MeSH Number(s) |
D12.644.276.100.800.200 D12.776.467.100.800.200 D23.529.100.800.200
|
| Concept/Terms |
Vascular Endothelial Growth Factor A- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor-A
- VEGF-A
- Vasculotropin
- VEGF
- Vascular Endothelial Growth Factor
- Vascular Permeability Factor
- Permeability Factor, Vascular
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor A".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor A".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor A" by people in this website by year, and whether "Vascular Endothelial Growth Factor A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 7 | 7 |
| 2000 | 0 | 5 | 5 |
| 2001 | 0 | 7 | 7 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 3 | 3 |
| 2004 | 4 | 4 | 8 |
| 2005 | 5 | 7 | 12 |
| 2006 | 0 | 3 | 3 |
| 2007 | 7 | 5 | 12 |
| 2008 | 5 | 10 | 15 |
| 2009 | 4 | 6 | 10 |
| 2010 | 2 | 6 | 8 |
| 2011 | 4 | 12 | 16 |
| 2012 | 5 | 8 | 13 |
| 2013 | 10 | 4 | 14 |
| 2014 | 9 | 10 | 19 |
| 2015 | 3 | 6 | 9 |
| 2016 | 5 | 3 | 8 |
| 2017 | 6 | 7 | 13 |
| 2018 | 3 | 4 | 7 |
| 2019 | 1 | 8 | 9 |
| 2020 | 3 | 3 | 6 |
| 2021 | 4 | 5 | 9 |
| 2022 | 1 | 7 | 8 |
| 2023 | 2 | 10 | 12 |
| 2024 | 3 | 6 | 9 |
| 2025 | 5 | 2 | 7 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor A" by people in Profiles.
-
Short-term effects of tetracycline use in patients with diabetic retinopathy. Can J Ophthalmol. 2025 12; 60(6):e858-e868.
-
Suppression of matrigel-induced choroidal neovascularization by AAV delivery of a novel anti-Scg3 antibody. Gene Ther. 2024 11; 31(11-12):587-593.
-
A method for rapid and reliable quantification of VEGF-cell binding activity. Biochem Biophys Res Commun. 2024 10 01; 727:150321.
-
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors. Pediatr Blood Cancer. 2024 03; 71(3):e30817.
-
Optimizing Visual Outcomes in Patients With Neovascular Age-Related Macular Degeneration: the Potential Value of Sustained Anti-VEGF Therapy. Ophthalmic Surg Lasers Imaging Retina. 2023 11; 54(11):654-659.
-
Forniceal deep brain stimulation in a mouse model of Rett syndrome increases neurogenesis and hippocampal memory beyond the treatment period. Brain Stimul. 2023 Sep-Oct; 16(5):1401-1411.
-
Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies. Int J Mol Sci. 2021 May 01; 22(9).
-
Combination of apolipoprotein-A-I/apolipoprotein-A-I binding protein and anti-VEGF treatment overcomes anti-VEGF resistance in choroidal neovascularization in mice. Commun Biol. 2020 07 16; 3(1):386.
-
Abicipar pegol for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2020 09; 20(9):999-1008.
-
Circular RNA CircFndc3b modulates cardiac repair after myocardial infarction via FUS/VEGF-A axis. Nat Commun. 2019 09 20; 10(1):4317.